Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Sebba

Rheumatology Palm Harbor, FL Medical Doctor

NPI 1629077243 CMS profile 1178088

33920 US Highway 19 North, Suite 241, Palm Harbor, FL 34684

Open in the dashboard

General payments

$587,644

736 records reported · program years 2019–2025

Research payments

$6,326

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,208 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Anthony Sebba of Palm Harbor, FL is reported in the CMS Open Payments database as having received $587,644 across 736 general payments and $6,326 in research payments paid to them. Separately, studies naming them as principal investigator received $13,208 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,491 8
2024 General $29,898 32
2023 General $71,864 91
2022 General $75,786 137
2021 General $54,468 59
2020 General $82,908 62
2020 Research $4,366 5
2019 General $263,229 347
2019 Research $1,960 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Sebba
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Anthony Sebba were reported at $9,491. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Anthony Sebba Rheumatology median Middle half National median
2019 $263,229 $744 $153–$2,687 $163
2020 $82,908 $462 $98–$2,027 $114
2021 $54,468 $531 $101–$2,153 $132
2022 $75,786 $627 $125–$2,303 $149
2023 $71,864 $741 $145–$2,524 $160
2024 $29,898 $830 $166–$2,660 $164
2025 $9,491 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $204,302 282 payments
  2. Genzyme Corporation $157,730 164 payments
  3. Genentech USA, Inc. $54,483 53 payments
  4. Sanofi-Aventis U.S. LLC $52,090 11 payments
  5. Eli Lilly and Company $33,445 58 payments
  6. Amgen Inc. $26,207 55 payments
  7. Gilead Sciences, Inc. $19,742 24 payments
  8. Regeneron Healthcare Solutions, Inc. $17,810 30 payments
  9. Radius Health, Inc. $11,371 13 payments
  10. UCB, Inc. $7,941 13 payments
  11. Other $2,525 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $428,544 177 payments
  2. Consulting Fee $78,255 24 payments
  3. Travel and Lodging $71,425 265 payments
  4. Food and Beverage $9,292 265 payments
  5. Education $129 5 payments
Products named General payments · program years 2019–2025
  1. TALTZ $122,064 168 payments
  2. KEVZARA Immunology $90,757 67 payments
  3. OLUMIANT $71,612 68 payments
  4. KEVZARA Rheumatology $67,990 69 payments
  5. Actemra $53,519 50 payments
  6. KEVZARA Immunology $37,964 20 payments
  7. KEVZARA Inflammation And Immunology $17,810 30 payments
  8. Prolia $16,156 33 payments
  9. Tymlos $11,348 12 payments
  10. EVENITY $9,997 18 payments
  11. Other $1,958 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $2,408 3 payments
  2. Eli Lilly and Company $1,960 1 payment
  3. F. Hoffmann-La Roche AG $1,561 1 payment
  4. Sanofi-Aventis U.S. LLC $398 1 payment

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$24,904

Of which drugs: $21,204

Medicare patients

26

Average age 76

Services billed

1,898

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
Arthritis 65%
High blood pressure 62%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEVZARA
  • GENZYME CORPORATION $27,976
$27,976 — —
TREMFYA
  • Janssen Biotech, Inc. $29
$29 — —
TALTZ
  • Lilly USA, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

742 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record